CSO & CEOFunction Therapeutics, Inc.Milwaukee, Wisconsin, United States
OC 19.4 - Modulation of Protease Activated Receptor-1 Signaling with Parmodulin 2 Attenuates Thrombo-inflammation and Acute Chest Syndrome in a Mouse Model of Sickle Cell Disease
Sunday, June 25, 202311:30 – 11:45 ET